Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company known for its innovative medicines. On August 1, 2025, UBS updated its rating for Regeneron to Neutral, maintaining a hold action. At the time, the stock price was $545.46. Regeneron competes in the pharmaceutical industry against companies like Amgen and Gilead Sciences.
In the second quarter of 2025, Regeneron reported a 4% increase in revenues, reaching $3.68 billion. This growth was driven by a 22% rise in global net sales of Dupixent®, totaling $4.34 billion. Despite this, the combined net sales of EYLEA HD® and EYLEA® decreased by 25% to $1.15 billion. The company's GAAP earnings per share (EPS) rose by 3% to $12.81, while the non-GAAP EPS increased by 12% to $12.89.
Regeneron received FDA approval for Lynozyfic™ (linvoseltamab) for treating relapsed or refractory multiple myeloma. Additionally, Dupixent was approved for bullous pemphigoid and chronic spontaneous urticaria (CSU). The FDA also accepted Libtayo®'s supplemental Biologics License Application (sBLA) for priority review in treating adjuvant cutaneous squamous cell carcinoma (CSCC).
The company in-licensed rights to a late-stage dual GLP-1/GIP receptor agonist and reported interim 26-week data from the Phase 2 COURAGE trial in obesity. Despite these advancements, Regeneron's shares declined by 1.6%, closing at $545.46 on Thursday. The stock has experienced a decrease of approximately 1.64%, translating to a drop of $9.12.
Regeneron's market capitalization stands at approximately $57.9 billion, with a trading volume of 1,406,489 shares. The stock's price has ranged from a low of $541.57 to a high of $558.22 during the trading day. Over the past year, the stock has reached a high of $1,211.20 and a low of $476.49.
